A new HPLC-MS/MS method for the simultaneous quantification of SGLT2 inhibitors and metformin in plasma and its application to a pharmacokinetic study in healthy volunteers.
human plasma
metformin
pharmacokinetics
quantification
sodium-glucose cotransporter-2 inhibitor
Journal
Biomedical chromatography : BMC
ISSN: 1099-0801
Titre abrégé: Biomed Chromatogr
Pays: England
ID NLM: 8610241
Informations de publication
Date de publication:
Nov 2019
Nov 2019
Historique:
received:
18
05
2019
revised:
10
07
2019
accepted:
17
07
2019
pubmed:
25
7
2019
medline:
16
1
2020
entrez:
25
7
2019
Statut:
ppublish
Résumé
Monitoring the plasma concentrations of metformin and sodium-glucose cotransporter-2 inhibitors (canagliflozin, dapagliflozin and empagliflozin) is essential for pharmacokinetic and bioequivalence studies and therapeutic monitoring. The present work therefore aimed to develop and validate a high-performance liquid chromatography coupled to tandem mass spectrometry (HPLC-MS/MS) method for the simultaneous quantification of these drugs in human plasma. The analyses were performed using an Agilent 1200 HPLC system coupled to an Applied Biosystems API 3200 triple quadrupole MS/MS with electrospray ionization in positive ion mode. After one-step protein precipitation of plasma with acetonitrile containing 0.1% formic acid, chromatographic separation was achieved on an Xbridge C
Substances chimiques
Benzhydryl Compounds
0
Glucosides
0
Sodium-Glucose Transporter 2 Inhibitors
0
Canagliflozin
0SAC974Z85
Metformin
9100L32L2N
empagliflozin
HDC1R2M35U
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e4663Informations de copyright
© 2019 John Wiley & Sons, Ltd.
Références
ADA (2017). Standards of Medical Care in Diabetes-2017. Diabetes Care, 40(1), S1-S135.
ANVISA. (2012). Ministério da Saúde. Retrieved May 16, 2016 from http://bvsms.saude.gov.br/bvs/saudelegis/anvisa/2012/rdc0027_17_05_2012.html.
Aubry, A. F., Gu, H., Magnier, R., Morgan, L., Xu, X., Tirmenstein, M., … Arnold, M. (2010). Validated LC-MS/MS methods for the determination of dapagliflozin, a sodium-glucose co-transporter 2 inhibitor in normal and ZDF rat plasma. Bioanalysis, 2(12), 2001-2009. https://doi.org/10.4155/bio.10.139
Ayoub, B. M., Mowaka, S., Elzanfaly, E. S., Ashoush, N., Elmazar, M. M., & Mousa, S. A. (2017). Pharmacokinetic evaluation of empagliflozin in healthy Egyptian volunteers using LC-MS/MS and comparison with other ethnic populations. Scientific Reports, 7(1), 2583. https://doi.org/10.1038/s41598-017-02895-7
Boulton, D. W., Chang, M., Griffen, S. C., Kitaura, C., Lubin, S., Pollack, A., & LaCreta, F. (2016). Fed and fasted single-dose assessment of bioequivalence of dapagliflozin and metformin extended-release fixed-dose combination tablets relative to single-component dapagliflozin and metformin extended-release tablets in healthy subjects. Clinical Therapeutics, 38(1), 99-109. https://doi.org/10.1016/j.clinthera.2015.11.010
Brazil (2012). Resolução RDC no. 27, May 17, 2012. https://portal.anvisa.gov.br/documents/33880/2568070/rdc0027_17_05_2012.pdf/c6edeb56-200d-4482-8a19-99fa11c33fd3
Chang, M., Liu, X., Cui, D., Liang, D., LaCreta, F., Griffen, S. C., … Boulton, D. W. (2015). Bioequivalence, food effect, and steady-state assessment of dapagliflozin/metformin extended-release fixed-dose combination tablets relative to single-component dapagliflozin and metformin extended-release tablets in healthy subjects. Clinical Therapeutics, 37(7), 1517-1528. https://doi.org/10.1016/j.clinthera.2015.05.004
Chen, L. Z., Jungnik, A., Mao, Y., Philip, E., Sharp, D., Unseld, A., … Macha, S. (2015). Biotransformation and mass balance of the SGLT2 inhibitor empagliflozin in healthy volunteers. Xenobiotica, 45(6), 520-529. https://doi.org/10.3109/00498254.2014.999141
Chen, X., Hu, P., Vaccaro, N., Polidori, D., Curtin, C. R., Stieltjes, H., … Devineni, D. (2015). Pharmacokinetics, pharmacodynamics, and safety of single-dose canagliflozin in healthy Chinese subjects. Clinical Therapeutics, 37(7), 1483-1492. https://doi.org/10.1016/j.clinthera.2015.04.015
de Bruin, T. W., Reele, S., Hamer-Maansson, J. E., Parikh, S., & Tang, W. (2016). Bioequivalence of fixed-dose combinations of dapagliflozin and metformin with single-component tablets in healthy subjects and the effect of food on bioavailability. Clinical Pharmacology in Drug Development, 5(2), 118-130. https://doi.org/10.1002/cpdd.220
Devineni, D., & Polidori, D. (2015). Clinical pharmacokinetic, pharmacodynamic, and drug-drug interaction profile of canagliflozin, a sodium-glucose co-transporter 2 inhibitor. Clinical Pharmacokinetics, 54(10), 1027-1041. https://doi.org/10.1007/s40262-015-0285-z
Devineni, D., Curtin, C. R., Polidori, D., Gutierrez, M. J., Murphy, J., Rusch, S., & Rothenberg, P. L. (2013). Pharmacokinetics and pharmacodynamics of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in subjects with type 2 diabetes mellitus. Journal of Clinical Pharmacology, 53(6), 601-610. https://doi.org/10.1002/jcph.88
Devineni, D., Manitpisitkul, P., Murphy, J., Skee, D., Wajs, E., Mamidi, R. N., … Usiskin, K. (2015a). Effect of canagliflozin on the pharmacokinetics of glyburide, metformin, and simvastatin in healthy participants. Clinical Pharmacology in Drug Development, 4(3), 226-236. https://doi.org/10.1002/cpdd.166
Devineni, D., Manitpisitkul, P., Murphy, J., Stieltjes, H., Ariyawansa, J., Di Prospero, N. A., & Rothenberg, P. (2015b). Effect of food on the pharmacokinetics of canagliflozin, a sodium glucose co-transporter 2 inhibitor, and assessment of dose proportionality in healthy participants. Clinical Pharmacology in Drug Development, 4(4), 279-286. https://doi.org/10.1002/cpdd.151
Devineni, D., Vaccaro, N., Murphy, J., Curtin, C., Mamidi, R. N., Weiner, S., … Rothenberg, P. (2015c). Effects of rifampin, cyclosporine A, and probenecid on the pharmacokinetic profile of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in healthy participants. International Journal of Clinical Pharmacology and Therapeutics, 53(2), 115-128. https://doi.org/10.5414/CP202158
Devineni, D., Vaccaro, N., Polidori, D., Stieltjes, H., & Wajs, E. (2015d). Single- and multiple-dose pharmacokinetics and pharmacodynamics of canagliflozin, a selective inhibitor of sodium glucose co-transporter 2, in healthy participants. International Journal of Clinical Pharmacology and Therapeutics, 53(2), 129-138. https://doi.org/10.5414/CP202218
FDA (2018). Guidance for industry. Bioanalytical method validation. US Food and Drug Administration: Rockville, MD.
Gallwitz, B. (2016). Novel therapeutic approaches in diabetes. Endocrine Development, 31, 43-56. https://doi.org/10.1159/000439372
Graham, G. G., Punt, J., Arora, M., Day, R. O., Doogue, M. P., Duong, J. K., … Williams, K. M. (2011). Clinical pharmacokinetics of metformin. Clinical Pharmacokinetics, 50(2), 81-98. https://doi.org/10.2165/11534750-000000000-00000
Hausner, H., Derving Karsbol, J., Holst, A. G., Jacobsen, J. B., Wagner, F. D., Golor, G., & Anderson, T. W. (2017). Effect of semaglutide on the pharmacokinetics of metformin, warfarin, atorvastatin and digoxin in healthy subjects. Clinical Pharmacokinetics, 56(11), 1391-1401. https://doi.org/10.1007/s40262-017-0532-6
Heise, T., Mattheus, M., Woerle, H. J., Broedl, U. C., & Macha, S. (2015). Assessing pharmacokinetic interactions between the sodium glucose cotransporter 2 inhibitor empagliflozin and hydrochlorothiazide or torasemide in patients with type 2 diabetes mellitus: A randomized, open-label, crossover study. Clinical Therapeutics, 37(4), 793-803. https://doi.org/10.1016/j.clinthera.2014.12.018
Heise, T., Seewaldt-Becker, E., Macha, S., Hantel, S., Pinnetti, S., Seman, L., & Woerle, H. J. (2013). Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes. Diabetes, Obesity & Metabolism, 15(7), 613-621. https://doi.org/10.1111/dom.12073
Heise, T., Seman, L., Macha, S., Jones, P., Marquart, A., Pinnetti, S., … Dugi, K. (2013). Safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple rising doses of empagliflozin in patients with type 2 diabetes mellitus. Diabetes Therapy, 4(2), 331-345. https://doi.org/10.1007/s13300-013-0030-2
Iijima, H., Kifuji, T., Maruyama, N., & Inagaki, N. (2015). Pharmacokinetics, pharmacodynamics, and safety of canagliflozin in Japanese patients with type 2 diabetes mellitus. Advances in Therapy, 32(8), 768-782. https://doi.org/10.1007/s12325-015-0234-0
Imamura, A., Kusunoki, M., Ueda, S., Hayashi, N., & Imai, Y. (2013). Impact of voglibose on the pharmacokinetics of dapagliflozin in Japanese patients with type 2 diabetes. Diabetes Therapy, 4(1), 41-49. https://doi.org/10.1007/s13300-012-0016-5
Ji, Q. C., Xu, X., Ma, E., Liu, J., Basdeo, S., Liu, G., … Arnold, M. E. (2015). Selective reaction monitoring of negative electrospray ionization acetate adduct ions for the bioanalysis of dapagliflozin in clinical studies. Analytical Chemistry, 87(6), 3247-3254. https://doi.org/10.1021/ac5037523
Kasichayanula, S., Chang, M., Hasegawa, M., Liu, X., Yamahira, N., LaCreta, F. P., … Boulton, D. W. (2011). Pharmacokinetics and pharmacodynamics of dapagliflozin, a novel selective inhibitor of sodium-glucose co-transporter type 2, in Japanese subjects without and with type 2 diabetes mellitus. Diabetes, Obesity & Metabolism, 13(4), 357-365. https://doi.org/10.1111/j.1463-1326.2011.01359.x
Kasichayanula, S., Chang, M., Liu, X., Shyu, W. C., Griffen, S. C., LaCreta, F. P., & Boulton, D. W. (2012). Lack of pharmacokinetic interactions between dapagliflozin and simvastatin, valsartan, warfarin, or digoxin. Advances in Therapy, 29(2), 163-177. https://doi.org/10.1007/s12325-011-0098-x
Kasichayanula, S., Liu, X., Griffen, S. C., Lacreta, F. P., & Boulton, D. W. (2013). Effects of rifampin and mefenamic acid on the pharmacokinetics and pharmacodynamics of dapagliflozin. Diabetes, Obesity & Metabolism, 15(3), 280-283. https://doi.org/10.1111/dom.12024
Kasichayanula, S., Liu, X., Lacreta, F., Griffen, S. C., & Boulton, D. W. (2014). Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2. Clinical Pharmacokinetics, 53(1), 17-27. https://doi.org/10.1007/s40262-013-0104-3
Kasichayanula, S., Liu, X., Pe Benito, M., Yao, M., Pfister, M., LaCreta, F. P., … Boulton, D. W. (2013). The influence of kidney function on dapagliflozin exposure, metabolism and pharmacodynamics in healthy subjects and in patients with type 2 diabetes mellitus. British Journal of Clinical Pharmacology, 76(3), 432-444. https://doi.org/10.1111/bcp.12056
Kasichayanula, S., Liu, X., Shyu, W. C., Zhang, W., Pfister, M., Griffen, S. C., … Boulton, D. W. (2011). Lack of pharmacokinetic interaction between dapagliflozin, a novel sodium-glucose transporter 2 inhibitor, and metformin, pioglitazone, glimepiride or sitagliptin in healthy subjects. Diabetes, Obesity & Metabolism, 13(1), 47-54. https://doi.org/10.1111/j.1463-1326.2010.01314.x
Macha, S., Dieterich, S., Mattheus, M., Seman, L. J., Broedl, U. C., & Woerle, H. J. (2013). Pharmacokinetics of empagliflozin, a sodium glucose cotransporter-2 (SGLT2) inhibitor, and metformin following co-administration in healthy volunteers. International Journal of Clinical Pharmacology and Therapeutics, 51(2), 132-140. https://doi.org/10.5414/CP201794
Macha, S., Mattheus, M., Pinnetti, S., Broedl, U. C., & Woerle, H. J. (2015). Pharmacokinetics of empagliflozin and pioglitazone after coadministration in healthy volunteers. Clinical Therapeutics, 37(7), 1503-1516. https://doi.org/10.1016/j.clinthera.2015.05.002
Marques, M. A., Soares Ade, S., Pinto, O. W., Barroso, P. T., Pinto, D. P., Ferreira-Filho, M., & Werneck-Barroso, E. (2007). Simple and rapid method determination for metformin in human plasma using high performance liquid chromatography tandem mass spectrometry: application to pharmacokinetic studies. Journal of Chromatography B, Analytical Technologies in the Biomedical and Life Sciences, 852(1-2), 308-316. https://doi.org/10.1016/j.jchromb.2007.01.030
Murphy, J., Wang, S. S., Stieltjes, H., Wajs, E., & Devineni, D. (2015). Effect of food on the pharmacokinetics of canagliflozin/metformin (150/1,000 mg) immediate-release fixed-dose combination tablet in healthy participants. International Journal of Clinical Pharmacology and Therapeutics, 53(3), 256-264. https://doi.org/10.5414/CP202233
Sarashina, A., Koiwai, K., Seman, L. J., Yamamura, N., Taniguchi, A., Negishi, T., … Dugi, K. A. (2013). Safety, tolerability, pharmacokinetics and pharmacodynamics of single doses of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in healthy Japanese subjects. Drug Metabolism and Pharmacokinetics, 28(3), 213-219. https://doi.org/10.2133/dmpk.DMPK-12-RG-082
SBD (2018). Diretrizes da sociedade brasileira de diabetes. https://www.diabetes.org.br/profissionais/images/2017/diretrizes/diretrizes-sbd-2017-2018.pdf
Scheen, A. J. (2014). Pharmacokinetic and pharmacodynamic profile of empagliflozin, a sodium glucose co-transporter 2 inhibitor. Clinical Pharmacokinetics, 53(3), 213-225. https://doi.org/10.1007/s40262-013-0126-x
Seman, L., Macha, S., Nehmiz, G., Simons, G., Ren, B., Pinnetti, S., … Dugi, K. (2013). Empagliflozin (BI 10773), a potent and selective SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects. Clinical Pharmacology in Drug Development, 2(2), 152-161. https://doi.org/10.1002/cpdd.16
Shyangdan, D. S., Uthman, O. A., & Waugh, N. (2016). SGLT-2 receptor inhibitors for treating patients with type 2 diabetes mellitus: A systematic review and network meta-analysis. BMJ Open, 6(2), e009417. https://doi.org/10.1136/bmjopen-2015-009417
Singh, H. P., Kaur, I., & Sharma, G. (2015). Sodium glucose co-transporter-2 (SGLT2) inhibitors as a new class of anti-diabetic drugs: Pharmacokinetics, efficacy and clinical significance. International Journal of Pharmaceutical Sciences Review and Research, 33(1), 40-47.
van Donge, T., Bielicki, J. A., van den Anker, J., & Pfister, M. (2018). Key components for antibiotic dose optimization of sepsis in neonates and infants. Frontiers in Pediatrics, 6, 325. https://doi.org/10.3389/fped.2018.00325
Vivian, E. (2015). Sodium-glucose cotransporter 2 inhibitors in the treatment of type 2 diabetes mellitus. The Diabetes Educator, 41, 5S-18S. https://doi.org/10.1177/0145721715607643
Wieling, J. (2002). LC-MS-MS experiences with internal standards. Chromatographia Supplement, 55, 107-113.
Yang, L., Li, H., Li, H., Bui, A., Chang, M., Liu, X., … Boulton, D. W. (2013). Pharmacokinetic and pharmacodynamic properties of single- and multiple-dose of dapagliflozin, a selective inhibitor of SGLT2, in healthy Chinese subjects. Clinical Therapeutics, 35(8), 1211-1222.e1212. https://doi.org/10.1016/j.clinthera.2013.06.017
Zhang, L., Tian, Y., Zhang, Z., & Chen, Y. (2007). Simultaneous determination of metformin and rosiglitazone in human plasma by liquid chromatography/tandem mass spectrometry with electrospray ionization: Application to a pharmacokinetic study. Journal of Chromatography B, Analytical Technologies in the Biomedical and Life Sciences, 854(1-2), 91-98. https://doi.org/10.1016/j.jchromb.2007.04.002
Zhao, X., Cui, Y., Zhao, S., Lang, B., Broedl, U. C., Salsali, A., … Macha, S. (2015). Pharmacokinetic and pharmacodynamic properties and tolerability of single- and multiple-dose once-daily empagliflozin, a sodium glucose cotransporter 2 inhibitor, in Chinese patients with type 2 diabetes mellitus. Clinical Therapeutics, 37(7), 1493-1502. https://doi.org/10.1016/j.clinthera.2015.05.001